These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37078339)

  • 1. Watchman device migration and embolization: A report from the NCDR LAAO Registry.
    Friedman DJ; Freeman JV; Zimmerman S; Tan Z; Pereira L; Faridi KF; Curtis JP
    J Cardiovasc Electrophysiol; 2023 May; 34(5):1192-1195. PubMed ID: 37078339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of left atrial appendage device closure following chronically failed surgical ligation.
    Ellis CR; Metawee M; Piana RN; Bennett JM; Pretorius M; Deegan RJ
    Heart Rhythm; 2019 Jan; 16(1):12-17. PubMed ID: 30012348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.
    Friedman DJ; Du C; Wang Y; Agarwal V; Varosy PD; Masoudi FA; Holmes DR; Reddy VY; Price MJ; Curtis JP; Freeman JV
    JACC Cardiovasc Interv; 2022 May; 15(9):950-961. PubMed ID: 35512918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices.
    Price MJ; Friedman DJ; Du C; Wang Y; Lin Z; Curtis JP; Freeman JV
    JACC Cardiovasc Interv; 2022 Nov; 15(21):2115-2123. PubMed ID: 36357014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left atrial appendage closure in patients with prohibitive anatomy: Insights from PINNACLE FLX.
    Ellis CR; Jackson GG; Kanagasundram AN; Mansour M; Sutton B; Houle VM; Kar S; Doshi S; Osorio J
    Heart Rhythm; 2021 Jul; 18(7):1153-1161. PubMed ID: 33957090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry.
    Darden D; Duong T; Du C; Munir MB; Han FT; Reeves R; Saw J; Zeitler EP; Al-Khatib SM; Russo AM; Minges KE; Curtis JP; Freeman JV; Hsu JC
    JAMA Cardiol; 2021 Nov; 6(11):1275-1284. PubMed ID: 34379072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry.
    Turagam MK; Lavu M; Afzal MR; Vuddanda V; Jazayeri MA; Parikh V; Atkins D; Bommana S; DI Biase L; Horton R; Bai R; Swarup V; Cheng J; Natale A; Lakkireddy D
    J Cardiovasc Electrophysiol; 2017 Feb; 28(2):139-146. PubMed ID: 27943538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices.
    Mansour MJ; Harnay E; Al Ayouby A; Mansourati V; Jobic Y; Gilard M; Le Ven F; Mansourati J
    J Interv Card Electrophysiol; 2022 Jun; 64(1):27-34. PubMed ID: 34002319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence and characteristics of candidates for percutaneous left atrial appendage occlusion using a WATCHMAN device among patients who underwent atrial fibrillation ablation in a Japanese population.
    Kemi Y; Yamashita E; Fujiwara T; Kario K; Sasaki T; Minami K; Miki Y; Goto K; Take Y; Nakamura K; Naito S
    J Echocardiogr; 2021 Dec; 19(4):243-249. PubMed ID: 34296416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unconventional combination of left atrial appendage device occlusion in patients with atrial fibrillation who needed concomitant catheter interventions for underlying structural heart disease.
    Raghuram P; Pavithran S; Sivakumar K
    Indian Heart J; 2020; 72(5):369-375. PubMed ID: 33189196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of percutaneous Watchman 2.5 device versus Amplatzer Amulet for left atrial appendage closure in patients with non-valvular atrial fibrillation: A systematic review and study-level meta-analysis.
    Yasmin F; Ali E; Moeed A; Zaidi F; Umar M; Virwani V
    PLoS One; 2024; 19(2):e0295804. PubMed ID: 38354181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation.
    Swaans MJ; Alipour A; Rensing BJ; Post MC; Boersma LV
    J Vis Exp; 2013 Feb; (72):e3818. PubMed ID: 23486416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.
    Galea R; De Marco F; Meneveau N; Aminian A; Anselme F; Gräni C; Huber AT; Teiger E; Iriart X; Babongo Bosombo F; Heg D; Franzone A; Vranckx P; Fischer U; Pedrazzini G; Bedogni F; Räber L; Valgimigli M
    Circulation; 2022 Mar; 145(10):724-738. PubMed ID: 34747186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion.
    Friedman DJ; Du C; Zimmerman S; Tan Z; Lin Z; Vemulapalli S; Kosinski AS; Piccini JP; Pereira L; Minges KE; Faridi KF; Masoudi FA; Curtis JP; Freeman JV
    Circ Cardiovasc Interv; 2024 Jun; 17(6):e013466. PubMed ID: 38889251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with the new Watchman FLX device: Data from two high-volume Sicilian centers. The FLX-iEST registry.
    Vizzari G; Grasso C; Sardone A; Mazzone P; Laterra G; Frazzetto M; Sacchetta G; Micari A; Tamburino C; Contarini M
    Catheter Cardiovasc Interv; 2022 Jul; 100(1):154-160. PubMed ID: 35592941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
    Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
    J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study.
    Galea R; Mahmoudi K; Gräni C; Elhadad S; Huber AT; Heg D; Siontis GCM; Brugger N; Sebag F; Windecker S; Valgimigli M; Landolff Q; Roten L; Amabile N; Räber L
    Europace; 2022 Oct; 24(9):1441-1450. PubMed ID: 35253840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
    Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
    J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous Left Atrial Appendage Closure with WATCHMAN™ device: peri-procedural and mid-term outcomes from the TRAPS Registry.
    Mazzone P; D'Angelo G; Regazzoli D; Molon G; Senatore G; Saccà S; Canali G; Amellone C; Turri R; Bella PD
    J Interv Card Electrophysiol; 2018 Jun; 52(1):47-52. PubMed ID: 29525913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.